Lineage Cell Therapeutics Inc (LCTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2022 | 12-2021 | 09-2021 | 06-2021 | 03-2021 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -7,087 | -43,270 | -14,029 | -6,204 | -1,416 |
| Depreciation Amortization | 178 | 887 | 701 | 503 | 296 |
| Income taxes - deferred | 0 | N/A | -1,181 | -169 | N/A |
| Accounts receivable | 50,321 | -857 | -104 | N/A | -135 |
| Other Working Capital | 27,124 | 21,096 | -195 | -852 | -1,344 |
| Other Operating Activity | -48,632 | -1,417 | -2,880 | -6,118 | -4,825 |
| Operating Cash Flow | $21,904 | $-23,561 | $-17,688 | $-12,840 | $-7,424 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -46 | -340 | -194 | -126 | -11 |
| Other Investing Activity | 0 | 10,085 | 10,085 | 10,085 | 10,085 |
| Investing Cash Flow | $-46 | $9,745 | $9,891 | $9,959 | $10,074 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | -8 | -20 | -13 | N/A | N/A |
| Common Stock Issued | 529 | 38,105 | 30,741 | 33,161 | 21,590 |
| Common Stock Repurchased | -8 | -54 | N/A | -27 | -13 |
| Other Financing Activity | 0 | -1,101 | 5,248 | -877 | -614 |
| Financing Cash Flow | $513 | $36,930 | $35,976 | $32,257 | $20,963 |
| Exchange Rate Effect | -42 | -20 | -34 | -43 | -80 |
| Beginning Cash Position | 56,277 | 33,183 | 33,183 | 33,183 | 33,183 |
| End Cash Position | 78,606 | 56,277 | 61,328 | 62,516 | 56,716 |
| Net Cash Flow | $22,329 | $23,094 | $28,145 | $29,333 | $23,533 |
| Free Cash Flow | |||||
| Operating Cash Flow | 21,904 | -23,561 | -17,688 | -12,840 | -7,424 |
| Capital Expenditure | -46 | -340 | -194 | -126 | -11 |
| Free Cash Flow | 21,858 | -23,901 | -17,882 | -12,966 | -7,435 |